AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01212822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT01212822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT04424056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab and Ruxolitinib (Advanced stage 3)
Description: administration of Tocilizumab and Ruxolitinib
Study NCT04424056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Treatment with drugs or procedures in routine clinical practice
Study NCT01341691 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chewing gum
Description: single piece of chewing gum containing specified amount of chitosan with or without extender chewed twice daily for 14 days
Study NCT01212822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection
Study NCT01212822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00539812 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: Standard 40 hour state mandated batterer intervention program
Study NCT00539812 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief Alcohol Intervention combined with standard care
Description: Brief alcohol intervention combined with standard 40 hour state mandated batterer intervention program
Study NCT02326506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VA-ELS pump speed variations
Description: Small variations in the pump speed of the veno-arterial extracorporeal life support (VA-ELS) pump
Study NCT03963466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: Oral tranexamic acid group(menstrual period>2days) 250mg bid（exclude menstrual period ）
Study NCT01341691 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: chewing gum
Description: single piece of chewing gum containing specified amount of chitosan with or without extender chewed twice daily for 14 days
Study NCT03963466 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 1064-nm Q-Switched fractional laser
Description: Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24 left side of cheek is selected to be treated with 1064-nm Q-Switched fractional laser therapy (8ms, 1.5±0.5J/cm2) once 4 weeks for a total of 5 times
Study NCT03963466 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 1064-nm Q-Switched laser
Description: Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24 right side of cheek is selected to be treated with 1064-nm Q-Switched laser therapy (8ms, 1.5±0.5J/cm2) once 4 weeks for a total of 5 times
Study NCT01292213 — intervention group
Intervention type: PROCEDURE
Intervention: Cough swab
Description: Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
Study NCT01292213 — intervention group
Intervention type: PROCEDURE
Intervention: Oropharyngeal swab
Description: Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
Study NCT01393886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Greater Curvature Plication (LGCP)
Description: This procedure creates a small sized stomach by folding the stomach twice into itself vertically. The functional capacity of the stomach is decreased by 80% of its normal(At least two rows of five continuous stitches are placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum).
Study NCT01249573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fascia therapy or transcutaneous fibrolysis
Description: fascia therapy or transcutaneous fibrolysis as treatment for an acute ankle distortion
Study NCT01249573 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fascia therapy or transcutaneous fibrolysis
Description: fascia therapy or transcutaneous fibrolysis as treatment for an acute ankle distortion
Study NCT04409483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir-Ritonavir Drug Combination
Description: 400mg/100mg taken orally twice daily for 14 days.
Study NCT04409483 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Paracetamol as needed for the symptomatic treatment of fever and vitamin C 1000 mg daily
Study NCT01292213 — intervention group
Intervention type: PROCEDURE
Intervention: Nasopharyngeal swabs
Description: Samples will be tested to determine and characterise the bacteria and viruses that may be associated with chronic cough.
Study NCT01292213 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample
Description: Samples will be tested to determine and characterise the immunological markers that may be associated with chronic cough.
Study NCT01292213 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoscopy/ bronchoalveolar lavage samples
Description: Samples will be tested to determine and characterise the bacteria, viruses and immunological markers that may be associated with chronic cough.
Study NCT01292213 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Questionnaire completion.
Study NCT03883828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate solution
Description: Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
Study NCT03883828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin Ointment
Description: Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
Study NCT04409483 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Paracetamol as needed for the symptomatic treatment of fever and vitamin C 1000 mg daily
Study NCT03140371 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High energy high protein peptide feed study
Description: Each patient will receive the high energy, high protein peptide-based feed for a period of up to 4 weeks (28 days). The feed will be available as an enteral tube feed in a 500ml bottle, and as a Vanilla flavoured oral nutritional supplement in a 200ml plastic bottle. The appropriate feed presentation (tube feed or oral nutritional supplement) and prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management, based on the patient's clinical requirement and preference, and the Dietitian's clinical judgement.~The study feed is classed as a 'Dietary Food for Special Medical Purposes' (EC Directive 1999/21/EC, 1999) .
Study NCT01115478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A
Description: Daily oral dose of 2500 IU from enrollment until delivery
Study NCT01115478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Description: Daily oral dose of 25 mg from enrollment until delivery
Study NCT01115478 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dose from enrollment until delivery
Study NCT02886624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir/Elbasvir
Description: Once-daily, oral grazoprevir/elbasvir combination therapy at fixed-dose (100mg/50mg) for 8 weeks
Study NCT02382861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist
Description: In the NAVA group, the level of NAVA is daily adjusted to obtain Eadimax corresponding to 60 % of Eadimax of the patient during the SBT to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.
Study NCT02382861 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive pressure support ventilation
Description: In the control group, the PSV is decreased of 2cmH2O daily or several times a day to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.
Study NCT03348735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Description: Application of Lidocaine 5% patch for 12 hours.
Study NCT03348735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin 8% Patch
Description: Application of Capsaicin 8% patch for
Study NCT03348735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Oral treatment with pregabalin (75mg capsules) will be used at optimized doses to best match clinical practice in Europe.
Study NCT01948531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gynomunal® gel
Description: A fixed quantity of the cosmetic product will be applied on the face (including the submental area) twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage according to the instructions received by the investigator during the basal visit (T0).
Study NCT04362553 — intervention group
Intervention type: DEVICE
Intervention: wearable vital signs sensor
Description: vital signs monitoring during standard of care procedures; TTE, swan-ganz catheterization
Study NCT00224471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK208141 vaccine
Description: 3 IM doses
Study NCT02366117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: Adapted training on the patients active participation, rehabilitation, independence, rights and wellbeing.
Study NCT02399605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulation
Description: Subcutaneous abdominal electrical stimulation
Study NCT01935375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CNM Interpersonal Psychotherapy
Description: Eight Weekly 50 minute sessions CNM Interpersonal Psychotherapy
Study NCT01935375 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual is psychotherapy provided by a mental health provider
Study NCT04718259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine
Description: The use of intrathecal bupivacaine will be compared to the use of intrathecal bupivacaine and midazolam.
Study NCT04718259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: midazolam
Study NCT04338919 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: PCI with stent implantation
Study NCT04338919 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: PCI with stent implantation
Study NCT04338919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor plus aspirin
Description: Ticagrelor plus aspirin
Study NCT04338919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor plus aspirin
Description: Ticagrelor plus aspirin
Study NCT01681823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PectaSol-C Modified Citrus Pectin (MCP)
Description: Oral administration of PectaSol-C MCP (4.8 grams in six capsules three times a day away from food).
Study NCT02718196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Training smartphone application
Description: Every evening the application provides a list of the planned bedtime activities as well as the recommended bedtime. The steps are 1) positive bedtime routine 2) bedtime fading 3)addressing nocturnal feeding 4) extinction protocol
Study NCT04235205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g)
Description: Patients with nonalcoholic fatty liver disease are administered Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g) for 16 weeks
Study NCT04235205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elobixibat 10mg + cholestyramine powder placebo
Description: Patients with nonalcoholic fatty liver disease are administered Elobixibat 10mg+ cholestyramine powder placebo for 16 weeks
Study NCT04235205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elobixibat placebo + cholestyramine powder 9g (cholestyramine 4g)
Description: Patients with nonalcoholic fatty liver disease are administered Elobixibat placebo+ cholestyramine powder 9g (cholestyramine 4g) for 16 weeks
Study NCT02945553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Neuromuscular electrical stimulation (NMES) will be performed 5 times/week for one hour each day. NMES will start within 1 week of injury and continue till 3 weeks following surgery.
Study NCT04235205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Elobixibat placebo + cholestyramine powder placebo
Description: Patients with nonalcoholic fatty liver disease are administered Elobixibat placebo+ cholestyramine powder placebo for 16 weeks
Study NCT02945553 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microstimulation
Description: Microstimulation will be performed 5 times/week for one hour each day. Microstimulation will start within 1 week of injury and continue till 3 weeks following surgery.
Study NCT02119039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RGTA OTR 4120 (CACICOL20)
Study NCT02119039 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Genteal HA eye drops
Study NCT03159364 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pathogen-specific CTLs
Description: Patients will receive approximately 1x10\^5\~1x10\^6 CTLs/kg as a single infusion via IV injection and may receive additional infusions.
Study NCT04390516 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: COViage
Description: The COViage machine learning algorithm is designed to predict mechanical ventilation and mortality within 24 hours after hospital admission.
Study NCT02440828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tobramycin inhalation
Description: tobramycin inhalation 300 mg twice daily
Study NCT02440828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: NaCl 0.9% inhalation 4 ml twice daily
Study NCT01969565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Study NCT01969565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT04674501 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac evaluation and blood sampling
Description: Patients in this cohort will undergo cardiac evaluation before and after thoracic irradiation.~The dose-volume parameters for each cardiac substructures will be estimated using artificial intelligence-based auto-segmentation of the heart in CT images. Dose-volume parameters that predict cardiotoxicity will be analyzed.~The patients who developed cardiotoxicity will undergo blood sampling to establish cardiomyocytes derived from induced pluripotent stem cells, which will be used for identifying the mechanisms of radiation-induced cardiotoxicity and therapeutic targets.
Study NCT02635347 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC)
Description: Each RIC intervention will comprise three cycles of 5 minutes of inflation followed by 5 minutes of deflation of a pneumatic tourniquet placed in mid-thigh.
Study NCT02635347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pneumatic tourniquet
Description: Portable Tourniquet System(PTSii, Delfi Medical Innovations, Inc.) used to perform RIC interventions.
Study NCT04519047 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: Beginning on treatment period, subjects will receive either Rejoint Gel or normal saline with PRP intra-articular injection twice for one month (Visit 3 and 4).
Study NCT04519047 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: Beginning on treatment period, subjects will receive either Rejoint Gel or normal saline with PRP intra-articular injection twice for one month (Visit 3 and 4).
Study NCT00546260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administration of iv bolus prior to angiography
Study NCT00546260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT060128 Potassium
Description: administration of iv bolus prior to angiography
Study NCT02367391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Text Messages
Description: Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.
Study NCT02367391 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Usual Care. All participants receive the active medication, Varenicline.
Study NCT02234024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation of dairy-derived concentrated gangliosides.
Study NCT00457158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALN optional filter
Description: J1 : ALN optional filter M3 : ALN optional filter removed
Study NCT04212611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INFRA ORBITAL BLOCK
Description: Bilateral infra orbital blocks is performed using 2-3 mL of 0.375% levobupivacaine (group L) or ropivacaine (group R).
Study NCT01609673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended.
Study NCT03257306 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ureteral double-J stent removal using magnet
Description: Double-J ureteric stent removed using magnet
Study NCT03257306 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ureteral double-J stent removal using cystoscopy
Description: Double-J ureteric stent removed using cystoscopy
Study NCT02021864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D3 50,000 unit
Description: vitamin D3 50,000 unit/week for 8 weeks
Study NCT02021864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prenatal multivitamin
Description: daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
Study NCT02021864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prenatal multivitamin
Description: daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
Study NCT02491528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: insulin Aspart injection
Description: Subcutaneous injection of insulin Aspart prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
Study NCT02491528 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: insulin Aspart injection (NovoRapid)
Description: Subcutaneous injection of insulin Aspart injection (NovoRapid) prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
Study NCT00670891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oxygen (Hyperbaric Oxygen Therapy)
Description: Current Accepted Applications of HBOT (2008) Jan 2003, ANDI International~1. Air or Gas Embolus~2. Decompression Illness~3. Carbon Monoxide poising~4. Clostridial Myonecrosis (Gas Gangrene)~5. Necrotizing Fasciitis~6. Crush Injury (Compartment syndromes)~7. Selected Problem Wounds~8. Compromised Skin Flaps or Grafts~9. Refractory Osteomyelitis~10. Exceptional Anemia due to Blood loss~11. Osteoradionecrosis~12. Thermal Burns and Radiation Tissue Damage~13. Diabetic Wounds~14. Intra-Cranial Abscess~15. Brain Injury and other Head Trauma~16. Cerebral Palsy~17. High Altitude Sickness~18. Lyme disease
Study NCT04460924 — intervention group
Intervention type: DRUG
Intervention: Integrase strand transfer inhibitors
Description: Integrase strand transfer inhibitors as post-exposure prophylaxis or as antiretroviral treatment
Study NCT01020162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitryptiline, gabapentin
Description: For amitryptiline starting dose 20-30 mg at night, increasing until clinical effect. For gabapentin was the initial dose 300 mg tid with rapid increases up to 800 mg tid.
Study NCT01020162 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection of the ilioinguinal nerve
Description: In general anaesthesia the nerve was identified and resected as central as possible
Study NCT04058808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Watchers
Description: online or in a weekly wellbeing workshop, there is a fee of £12.95 per month, this is a healthy lifestyle programme based on food items having a point attached to them depending on the calorie, fat and sugar content. Each member has a specific number of points per day to use on their meals. The healthier foods have fewer points therefore you can eat more of them.